Status:

COMPLETED

Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters

Lead Sponsor:

Movetis

Conditions:

Constipation

Eligibility:

All Genders

18-50 years

Phase:

PHASE1

Brief Summary

This is a 2-arm, parallel-group active- and placebo-controlled, double-blind randomised study, stratified by gender and with a hybrid crossover group design, to compare treatment with prucalopride 2 m...

Detailed Description

A total number of 120 healthy subjects (with an approximate 1:1 female:male ratio) are planned to be randomised. Day 1: a baseline ECG profile. Day 1: Group 1 will receive prucalopride, Group 2a will...

Eligibility Criteria

Inclusion

  • Main Inclusion Criteria:
  • Healthy volunteers aged between 18 to 50 years.
  • Body mass index (BMI) between 18 and 30 kg/m2.
  • Female subjects must:
  • be of childbearing potential with a negative serum β-human chorionic gonadotropin (β-HCG) test at screening, and be willing and able to use medically acceptable double barrier methods of birth control, throughout the whole study; or
  • be postmenopausal; or
  • have received surgical sterilisation at least 6 months before screening; AND
  • females must not be receiving hormone replacement therapy (HRT).
  • Main exclusion Criteria:
  • Abnormal QTcF and/or heart rate/blood pressure values at baseline.
  • Subjects with ECG abnormalities that may interfere with the accurate assessment of the QT interval.
  • Subjects with known cardiovascular disorders.
  • Subjects with known clinically significant arrhythmias.
  • Subjects with risk factors e.g., Torsades de Pointes.
  • Subjects with clinically relevant, abnormal serum electrolytes or complete blood count (CBC) at screening.
  • Female subjects who are lactating or pregnant.
  • Subjects suffering from other significant medical conditions.
  • Subjects with a known allergy or sensitivity to moxifloxacin, or to prucalopride.
  • Subjects with a positive screening test for hepatitis B, hepatitis C, or HIV at screening.

Exclusion

    Key Trial Info

    Start Date :

    January 1 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2009

    Estimated Enrollment :

    120 Patients enrolled

    Trial Details

    Trial ID

    NCT00903747

    Start Date

    January 1 2009

    End Date

    May 1 2009

    Last Update

    May 18 2009

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters | DecenTrialz